The Melanocyte Stimulating Hormone Receptor pipeline drugs market research report outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Melanocyte Stimulating Hormone Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Oncology, Immunology, and Dermatology which include the indications Diabetic Retinopathy, Uveitis, Metastatic Melanoma, Skin Cancer, Autoimmune Disorders, Rheumatoid Arthritis, Vitiligo, and Unspecified Dermatological Disorders. It also reviews key players involved in Melanocyte Stimulating Hormone Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Melanocyte Stimulating Hormone Receptor pipeline targets constitutes close to 18 molecules. Out of which, approximately 18 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 4, 3, 3, 6, and 1 respectively.
Melanocyte Stimulating Hormone Receptor overview
Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein–coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.
For a complete picture of Melanocyte Stimulating Hormone Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
